SG11202102417TA - Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k) - Google Patents
Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)Info
- Publication number
- SG11202102417TA SG11202102417TA SG11202102417TA SG11202102417TA SG11202102417TA SG 11202102417T A SG11202102417T A SG 11202102417TA SG 11202102417T A SG11202102417T A SG 11202102417TA SG 11202102417T A SG11202102417T A SG 11202102417TA SG 11202102417T A SG11202102417T A SG 11202102417TA
- Authority
- SG
- Singapore
- Prior art keywords
- ube2k
- methods
- treating cancer
- conjugating enzyme
- ubiquitin conjugating
- Prior art date
Links
- 101000644689 Homo sapiens Ubiquitin-conjugating enzyme E2 K Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102100020696 Ubiquitin-conjugating enzyme E2 K Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729348P | 2018-09-10 | 2018-09-10 | |
| PCT/US2019/050465 WO2020055906A1 (en) | 2018-09-10 | 2019-09-10 | Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102417TA true SG11202102417TA (en) | 2021-04-29 |
Family
ID=69778426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102417TA SG11202102417TA (en) | 2018-09-10 | 2019-09-10 | Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k) |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210252036A1 (ja) |
| EP (1) | EP3849543A4 (ja) |
| JP (1) | JP2022500378A (ja) |
| KR (1) | KR20210057121A (ja) |
| CN (1) | CN112996504A (ja) |
| AU (1) | AU2019339896A1 (ja) |
| BR (1) | BR112021004417A2 (ja) |
| CA (1) | CA3112191A1 (ja) |
| IL (1) | IL281327A (ja) |
| MA (1) | MA53623A (ja) |
| MX (1) | MX2021002818A (ja) |
| SG (1) | SG11202102417TA (ja) |
| WO (1) | WO2020055906A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11091447B2 (en) * | 2020-01-03 | 2021-08-17 | Berg Llc | UBE2K modulators and methods for their use |
| CA3238430A1 (en) * | 2021-11-17 | 2023-05-25 | Berg Llc | Compounds for use in treating gastric cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8298756B2 (en) * | 2004-08-11 | 2012-10-30 | Albert Einstein College Of Medicine Of Yeshiva University | Isolation, gene expression, and chemotherapeutic resistance of motile cancer cells |
| WO2008052441A1 (en) * | 2006-11-02 | 2008-05-08 | Lan Huang | Inhibitors for disrupting the interaction of ubiquitination related enzymes and uses thereof |
| KR101525122B1 (ko) * | 2013-08-05 | 2015-06-03 | 광주과학기술원 | Ｕｂｂ 넉다운에 의한 암의 예방 또는 치료 |
| CN106132436B (zh) * | 2014-02-21 | 2021-06-15 | Ibc药品公司 | 通过诱导对trop-2表达细胞的免疫应答的疾病疗法 |
-
2019
- 2019-09-10 KR KR1020217010620A patent/KR20210057121A/ko unknown
- 2019-09-10 MA MA053623A patent/MA53623A/fr unknown
- 2019-09-10 AU AU2019339896A patent/AU2019339896A1/en active Pending
- 2019-09-10 US US17/274,405 patent/US20210252036A1/en active Pending
- 2019-09-10 JP JP2021513242A patent/JP2022500378A/ja active Pending
- 2019-09-10 SG SG11202102417TA patent/SG11202102417TA/en unknown
- 2019-09-10 WO PCT/US2019/050465 patent/WO2020055906A1/en unknown
- 2019-09-10 MX MX2021002818A patent/MX2021002818A/es unknown
- 2019-09-10 EP EP19861199.8A patent/EP3849543A4/en active Pending
- 2019-09-10 CN CN201980073592.0A patent/CN112996504A/zh active Pending
- 2019-09-10 BR BR112021004417-5A patent/BR112021004417A2/pt not_active Application Discontinuation
- 2019-09-10 CA CA3112191A patent/CA3112191A1/en active Pending
-
2021
- 2021-03-08 IL IL281327A patent/IL281327A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020055906A1 (en) | 2020-03-19 |
| MA53623A (fr) | 2021-07-21 |
| CA3112191A1 (en) | 2020-03-19 |
| CN112996504A (zh) | 2021-06-18 |
| KR20210057121A (ko) | 2021-05-20 |
| AU2019339896A1 (en) | 2021-04-08 |
| IL281327A (en) | 2021-04-29 |
| JP2022500378A (ja) | 2022-01-04 |
| WO2020055906A8 (en) | 2021-01-07 |
| BR112021004417A2 (pt) | 2021-06-01 |
| EP3849543A1 (en) | 2021-07-21 |
| EP3849543A4 (en) | 2022-11-30 |
| MX2021002818A (es) | 2021-07-15 |
| US20210252036A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3548071A4 (en) | METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES | |
| EP3423488A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| EP3258966A4 (en) | Methods, compositions, and kits for treatment of cancer | |
| EP3464643A4 (en) | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER | |
| EP3606531A4 (en) | CANCER TREATMENT METHODS | |
| EP3442946A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| EP3468548A4 (en) | METHOD FOR THE TREATMENT OF LATIVAL CANCER | |
| EP3775171A4 (en) | METHODS OF TREATING MINIMAL RESIDUAL CANCER | |
| EP3471830A4 (en) | EZH2 INHIBITORS TO TREAT CANCER | |
| EP3787625A4 (en) | METHODS OF TREATMENT OF CANCER | |
| EP3522887A4 (en) | METHODS OF TREATING BILARIAN CANCER | |
| EP3886867A4 (en) | METHODS OF TREATMENT OF WHSC1 OVEREXPRESSING CANCER BY INHIBITION OF SETD2 | |
| EP3487999A4 (en) | METHODS OF TREATING CANCER | |
| IL281327A (en) | Methods for treating cancer by inhibiting ubiquitin-capsulating enzyme E2 K (UBE2K) | |
| EP3630080A4 (en) | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER | |
| EP3908650A4 (en) | METHODS OF TREATMENT OF CANCER | |
| EP3723765A4 (en) | CANCER TREATMENT METHODS | |
| IL283885A (en) | cxcr7 inhibitors for cancer therapy | |
| IL281600A (en) | Methods of treating cancer | |
| IL277981A (en) | Cancer treatment methods | |
| EP3442564A4 (en) | COMPOSITION OF PROENZYMES FOR THE TREATMENT OF CANCER | |
| EP3793548A4 (en) | COMPOUNDS FOR THE TREATMENT OF PANCREATIC CANCER | |
| EP3565530A4 (en) | TREATMENT OF LATIVAL CANCER | |
| EP4072561A4 (en) | CANCER TREATMENT METHODS | |
| EP3669279A4 (en) | METHOD OF TREATMENT OF CANCER BY INHIBITION OF SETD2 |